Tumor immunotherapy has become an attractive strategy for treating cancer, with a particular focus on targeting programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated antigen-4 (CTLA4)2. The gene discussed is CD274; the disease is neoplasm.